K. Hearn, M. Ahn, L. Bevan, G. Chessari, M. Clark, B. Cons, J. Espana-agusti, K. Ferro, A. Howard, J. Lyons, V. Martins, C. Morgillo, N. Palmer, M. Rapti, A. Shah, T. Smyth, M. Unbekandt, D. Varshney, C. Hamlett
{"title":"42 (PB030):一种新型小分子 CBP/p300 HAT 结构域抑制剂在临床前物种中显示出强大的体内活性和良好的安全性特征","authors":"K. Hearn, M. Ahn, L. Bevan, G. Chessari, M. Clark, B. Cons, J. Espana-agusti, K. Ferro, A. Howard, J. Lyons, V. Martins, C. Morgillo, N. Palmer, M. Rapti, A. Shah, T. Smyth, M. Unbekandt, D. Varshney, C. Hamlett","doi":"10.1016/j.ejca.2024.114570","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"42 (PB030): A novel small-molecule CBP/p300 HAT domain inhibitor demonstrates potent in vivo activity and a favorable safety profile in preclinical species\",\"authors\":\"K. Hearn, M. Ahn, L. Bevan, G. Chessari, M. Clark, B. Cons, J. Espana-agusti, K. Ferro, A. Howard, J. Lyons, V. Martins, C. Morgillo, N. Palmer, M. Rapti, A. Shah, T. Smyth, M. Unbekandt, D. Varshney, C. Hamlett\",\"doi\":\"10.1016/j.ejca.2024.114570\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924012619\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012619","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
42 (PB030): A novel small-molecule CBP/p300 HAT domain inhibitor demonstrates potent in vivo activity and a favorable safety profile in preclinical species
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.